Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis
Overview
Authors
Affiliations
Background And Aims: Studies are needed to determine the long-term effects of bariatric surgery for patients with nonalcoholic steatohepatitis (NASH). We evaluated sequential liver samples, collected the time of bariatric surgery and 1 and 5 years later, to assess the long-term effects of bariatric surgery in patients with NASH.
Methods: We performed a prospective study of 180 severely obese patients with biopsy-proven NASH, defined by the NASH clinical research network histologic scores. The patients underwent bariatric surgery at a single center in France and were followed for 5 years. We obtained liver samples from 125 of 169 patients (76%) having reached 1 year and 64 of 94 patients (68%) having reached 5 years after surgery. The primary endpoint was the resolution of NASH without worsening of fibrosis at 5 years. Secondary end points were improvement in fibrosis (reduction of ≥1 stage) at 5 years and regression of fibrosis and NASH at 1 and 5 years.
Results: At 5 years after bariatric surgery, NASH was resolved, without worsening fibrosis, in samples from 84% of patients (n = 64; 95% confidence interval, 73.1%-92.2%). Fibrosis decreased, compared with baseline, in samples from 70.2% of patients (95% CI, 56.6%-81.6%). Fibrosis disappeared from samples from 56% of all patients (95% CI, 42.4%-69.3%) and from samples from 45.5% of patients with baseline bridging fibrosis. Persistence of NASH was associated with no decrease in fibrosis and less weight loss (reduction in body mass index of 6.3 ± 4.1 kg/m in patients with persistent NASH vs reduction of 13.4 ± 7.4 kg/m; P = .017 with resolution of NASH). Resolution of NASH was observed at 1 year after bariatric surgery in biopsies from 84% of patients, with no significant recurrence between 1 and 5 years (P = .17). Fibrosis began to decrease by 1 year after surgery and continued to decrease until 5 years (P < .001).
Conclusions: In a long-term follow-up of patients with NASH who underwent bariatric surgery, we observed resolution of NASH in liver samples from 84% of patients 5 years later. The reduction of fibrosis is progressive, beginning during the first year and continuing through 5 years.
Metabolic dysfunction-associated steatotic liver disease in adults.
Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.
PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.
Eslam M, Fan J, Yu M, Wong V, Cua I, Liu C Hepatol Int. 2025; .
PMID: 40016576 DOI: 10.1007/s12072-024-10774-3.
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.
Takawy M, Abdelmalek M Curr Diab Rep. 2025; 25(1):23.
PMID: 39964660 DOI: 10.1007/s11892-025-01579-1.
MetALD: Clinical aspects, pathophysiology and treatment.
Gratacos-Gines J, Arino S, Sancho-Bru P, Bataller R, Pose E JHEP Rep. 2025; 7(2):101250.
PMID: 39897615 PMC: 11782861. DOI: 10.1016/j.jhepr.2024.101250.
Yan M, Cui Y, Xiang Q Theranostics. 2025; 15(5):1715-1740.
PMID: 39897543 PMC: 11780521. DOI: 10.7150/thno.106597.